

Full title of the Clinical Trial: Phase II trial of Pembrolizumab in combination with Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer (TOPIC)

EudraCT Number: 2017-002824-26

Sponsor: Vall d'Hebron Institute of Oncology (VHIO)

Represented by (name): Marta Carboneras

Reason why final clinical trial results are not available: The duration of recruitment was longer than expected which impacted on the planned timelines for the analysis of the results. We are currently finalizing the final statistical analysis on all pre-specified outcome measures. Consequently, no results are available for this trial.

Preliminary results have been presented on congresses.

- Oaknin A, Rubio MJ, Fariñas L, Redondo A, Yubero A, Gil M, et al. 2732 - A phase 2 study of pembrolizumab in combination with doxorubicin in advanced, recurrent or metastatic endometrial cancer. *Annals of Oncology* (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250
- Piulats J, Fariñas-Madrid L, Santacana M, et al 731 Biomarker analysis of the phase 2 study of pembrolizumab in combination with doxorubicin in advanced endometrial cancer: TOPIC trial/VHIO10001 *International Journal of Gynecologic Cancer* 2021;31:A118-A119.

Date and Signature of Sponsor representative:



10 JUNE 2022